pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$LXRXLEXICON PHARMACEUTICALS, INC.

$LXRX2.1800-9.54%
The Woodlands, TX, USupdated 2h ago

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 2: 1Marketed: 1
1Phase 21Marketed
Marketed
sotagliflozin
Hypertrophic Cardiomyopathy
Sodium/glucose cotransporter 1Sodium/glucose cotransporter 2
Phase 2
pilavapadin phosphate
Diabetic Neuropathic Pain

📅 Upcoming

Nov 5, 2026
earnings
$LXRX2.1800-9.54%
in 3mo
LEXICON PHARMACEUTICALS, INC. earnings
LEXICON PHARMACEUTICALS, INC.
→

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathyrecruitingn=500
  • phase2Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgiacompletedn=79
  • phase2A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)completedn=496
  • phase2Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Paincompletedn=319

Insider activity

source: SEC Form 4

open-market buys + sells

  • Feb 25, 26BUYDEBBANE RAYMOND· director2,000 sh @ $1.49$3K↗
  • Feb 23, 26BUYDEBBANE RAYMOND· director100,000 sh @ $1.47$147K↗
routine RSU / option mechanics (6)
  • Feb 28, 26tax coverExton Michael · Chief Executive Officer204,831 sh
  • Feb 28, 26tax coverGranowitz Craig B · SVP, Chief Medical Officer109,098 sh
  • Feb 28, 26tax coverCrum Brian T · SVP, General Counsel & Secr.105,019 sh
  • Feb 28, 26tax coverDeFrancesco Lisa · SVP, IR and Corp Comm74,572 sh
  • Feb 28, 26tax coverMcDermott Wendy · SVP, Human Resources68,107 sh
  • Feb 28, 26tax coverCoiante Scott M · SVP, Chief Financial Officer54,881 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
No open roles indexed yet — view LEXICON PHARMACEUTICALS, INC. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$LXRX
SEC CIK
0001062822
country
US
source
sec_tickers
top tags
Cardiology1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 12m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?